{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:00:55Z","timestamp":1790352055358,"version":"4.1.0"},"reference-count":127,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","mayoclinicproceedings.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.mayocp.2016.05.015","type":"journal-article","created":{"date-parts":[[2016,8,4]],"date-time":"2016-08-04T23:38:38Z","timestamp":1470353918000},"page":"1189-1211","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":68,"title":["Thrombotic Microangiopathy Care Pathway: A Consensus Statement for the Mayo Clinic Complement Alternative Pathway-Thrombotic Microangiopathy (CAP-TMA) Disease-Oriented Group"],"prefix":"10.1016","volume":"91","author":[{"given":"Ronald S.","family":"Go","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey L.","family":"Winters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria A.","family":"Willrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roshini S.","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatem","family":"Amer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Hogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariela L.","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeev","family":"Sethi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl L.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajiv K.","family":"Pruthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aneel A.","family":"Ashrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando C.","family":"Fervenza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"II","given":"Carl H.","family":"Cramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vilmarie","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra P.","family":"Wolanskyj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan D.","family":"Thom\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Christopher","family":"Hook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald S.","family":"Go","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey L.","family":"Winters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria A.","family":"Willrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roshini S.","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatem","family":"Amer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Hogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariela L.","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeev","family":"Sethi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl L.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajiv K.","family":"Pruthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aneel A.","family":"Ashrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando C.","family":"Fervenza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"II","given":"Carl H.","family":"Cramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Christopher","family":"Hook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vesna D.","family":"Garovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer C.","family":"Yui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana Perez","family":"Botero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.mayocp.2016.05.015_bib1","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1056\/NEJMra1312353","article-title":"Syndromes of thrombotic microangiopathy","volume":"371","author":"George","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"2 Suppl","key":"10.1016\/j.mayocp.2016.05.015_bib2","doi-asserted-by":"crossref","first-page":"53S","DOI":"10.1378\/chest.11-2288","article-title":"Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Guyatt","year":"2012","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.mayocp.2016.05.015_bib3","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/ajh.10450","article-title":"Morphologic diagnosis of thrombotic thrombocytopenic purpura","volume":"75","author":"Burns","year":"2004","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.mayocp.2016.05.015_bib4","doi-asserted-by":"crossref","first-page":"e10208","DOI":"10.1371\/journal.pone.0010208","article-title":"Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience","volume":"5","author":"Coppo","year":"2010","journal-title":"PLoS One"},{"issue":"20","key":"10.1016\/j.mayocp.2016.05.015_bib5","doi-asserted-by":"crossref","first-page":"4060","DOI":"10.1182\/blood-2010-07-271445","article-title":"How I treat patients with thrombotic thrombocytopenic purpura: 2010","volume":"116","author":"George","year":"2010","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.mayocp.2016.05.015_bib6","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/BF01726874","article-title":"Thrombotic thrombocytopenic purpura without anemia","volume":"64","author":"Barnert","year":"1986","journal-title":"Klin Wochenschr"},{"issue":"3","key":"10.1016\/j.mayocp.2016.05.015_bib7","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/01.SMJ.0000136231.83564.F6","article-title":"Thrombotic thrombocytopenic purpura without schistocytes on the peripheral blood smear","volume":"98","author":"Daram","year":"2005","journal-title":"South Med J"},{"key":"10.1016\/j.mayocp.2016.05.015_bib8","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1182\/asheducation.V2012.1.617.3798924","article-title":"Atypical hemolytic uremic syndrome: what is it, how is it diagnosed, and how is it treated?","volume":"2012","author":"Nester","year":"2012","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"4","key":"10.1016\/j.mayocp.2016.05.015_bib9","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood-2014-11-611335","article-title":"Drug-induced thrombotic microangiopathy: a systematic review of published reports","volume":"125","author":"Al-Nouri","year":"2015","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.mayocp.2016.05.015_bib10","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/ajh.23960","article-title":"Drug-induced thrombotic microangiopathy: experience of the Oklahoma registry and the BloodCenter of Wisconsin","volume":"90","author":"Reese","year":"2015","journal-title":"Am J Hematol"},{"issue":"17","key":"10.1016\/j.mayocp.2016.05.015_bib11","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJMra0902814","article-title":"Atypical hemolytic-uremic syndrome","volume":"361","author":"Noris","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.mayocp.2016.05.015_bib12","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.blre.2013.01.001","article-title":"The emerging concept of residual ADAMTS13 activity in ADAMTS13-deficient thrombotic thrombocytopenic purpura","volume":"27","author":"Lotta","year":"2013","journal-title":"Blood Rev"},{"issue":"4","key":"10.1016\/j.mayocp.2016.05.015_bib13","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/j.1538-7836.2007.02438.x","article-title":"Hyperbilirubinemia interferes with ADAMTS-13 activity measurement by FRETS-VWF73 assay: diagnostic relevance in patients suffering from acute thrombotic microangiopathies","volume":"5","author":"Meyer","year":"2007","journal-title":"J\u00a0Thromb Haemost"},{"issue":"8","key":"10.1016\/j.mayocp.2016.05.015_bib14","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1111\/jth.12319","article-title":"An optimized fluorogenic ADAMTS13 assay with increased sensitivity for the investigation of patients with thrombotic thrombocytopenic purpura","volume":"11","author":"Muia","year":"2013","journal-title":"J\u00a0Thromb Haemost"},{"issue":"3","key":"10.1016\/j.mayocp.2016.05.015_bib15","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1182\/blood-2004-03-1101","article-title":"Proteolytic inactivation of ADAMTS13 by thrombin and plasmin","volume":"105","author":"Crawley","year":"2005","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.mayocp.2016.05.015_bib16","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1182\/blood-2009-01-195461","article-title":"Leukocyte proteases cleave von Willebrand factor at or near the ADAMTS13 cleavage site","volume":"114","author":"Raife","year":"2009","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.mayocp.2016.05.015_bib17","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1182\/blood-2004-11-4490","article-title":"ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases","volume":"106","author":"Rieger","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.mayocp.2016.05.015_bib18","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1182\/asheducation.V2012.1.610.3798654","article-title":"Role of ADAMTS13 in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura","volume":"2012","author":"Kremer Hovinga","year":"2012","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"1","key":"10.1016\/j.mayocp.2016.05.015_bib19","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/humu.21143","article-title":"ADAMTS13 mutations and polymorphisms in congenital thrombotic thrombocytopenic purpura","volume":"31","author":"Lotta","year":"2010","journal-title":"Hum Mutat"},{"issue":"3","key":"10.1016\/j.mayocp.2016.05.015_bib20","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1365-2141.2012.09168.x","article-title":"The use of \u2018real-time\u2019 complement analysis to differentiate atypical haemolytic uraemic syndrome from other forms of thrombotic microangiopathies","volume":"158","author":"Prohaszka","year":"2012","journal-title":"Br\u00a0J Haematol"},{"issue":"24","key":"10.1016\/j.mayocp.2016.05.015_bib21","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1182\/blood-2013-12-547067","article-title":"Biomarkers of terminal complement activation confirm the diagnosis of aHUS and differentiate aHUS from TTP","volume":"123","author":"Cataland","year":"2014","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.mayocp.2016.05.015_bib22","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1365-3083.2006.01729.x","article-title":"Clinical aspects and molecular basis of primary deficiencies of complement component C3 and its regulatory proteins factor I and factor H","volume":"63","author":"S Reis","year":"2006","journal-title":"Scand J Immunol"},{"issue":"16","key":"10.1016\/j.mayocp.2016.05.015_bib23","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1016\/j.molimm.2007.06.150","article-title":"Complement analysis in the 21st century","volume":"44","author":"Mollnes","year":"2007","journal-title":"Mol Immunol"},{"issue":"11","key":"10.1016\/j.mayocp.2016.05.015_bib24","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1182\/blood-2014-02-558296","article-title":"Dynamics of complement activation in aHUS and how to monitor eculizumab therapy","volume":"124","author":"Noris","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.mayocp.2016.05.015_bib25","first-page":"119","article-title":"The impact of eculizumab in complement assays","volume":"67","author":"Andreguetto","year":"2015","journal-title":"Mol Immunol"},{"issue":"5","key":"10.1016\/j.mayocp.2016.05.015_bib26","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1182\/blood-2014-03-560540","article-title":"Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab","volume":"125","author":"Peffault de Latour","year":"2015","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.mayocp.2016.05.015_bib27","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1681\/ASN.2012090884","article-title":"Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype","volume":"24","author":"Bresin","year":"2013","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.mayocp.2016.05.015_bib28","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1681\/ASN.2013050453","article-title":"Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome","volume":"25","author":"Bu","year":"2014","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"9","key":"10.1016\/j.mayocp.2016.05.015_bib29","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/gim.2013.92","article-title":"ACMG clinical laboratory standards for next-generation sequencing","volume":"15","author":"Rehm","year":"2013","journal-title":"Genet Med"},{"key":"10.1016\/j.mayocp.2016.05.015_bib30","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/1471-2105-15-109","article-title":"Copy number variation detection using next generation sequencing read counts","volume":"15","author":"Wang","year":"2014","journal-title":"BMC Bioinformatics"},{"issue":"5","key":"10.1016\/j.mayocp.2016.05.015_bib31","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/ng.2590","article-title":"Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome","volume":"45","author":"Lemaire","year":"2013","journal-title":"Nat Genet"},{"issue":"5","key":"10.1016\/j.mayocp.2016.05.015_bib32","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/ng.2622","article-title":"DGKE and atypical HUS","volume":"45","author":"Quaggin","year":"2013","journal-title":"Nat Genet"},{"issue":"4","key":"10.1016\/j.mayocp.2016.05.015_bib33","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa0810739","article-title":"Thrombomodulin mutations in atypical hemolytic-uremic syndrome","volume":"361","author":"Delvaeye","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mayocp.2016.05.015_bib34","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/978-1-62703-724-2_27","article-title":"Detection of cell membrane-bound CD46 using flow cytometry","volume":"1100","author":"Kolev","year":"2014","journal-title":"Methods Mol Biol"},{"issue":"4","key":"10.1016\/j.mayocp.2016.05.015_bib35","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1055\/s-0034-1375701","article-title":"Pathology of renal diseases associated with dysfunction of the alternative pathway of complement: C3 glomerulopathy and atypical hemolytic uremic syndrome (aHUS)","volume":"40","author":"Sethi","year":"2014","journal-title":"Semin Thromb Hemost"},{"issue":"8","key":"10.1016\/j.mayocp.2016.05.015_bib36","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1106920","article-title":"Origins of the E.\u00a0coli strain causing an outbreak of hemolytic-uremic syndrome in Germany","volume":"365","author":"Rasko","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.mayocp.2016.05.015_bib37","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1128\/JCM.02013-08","article-title":"Rapid and sensitive detection of Shiga toxin-producing Escherichia coli from nonenriched stool specimens by real-time PCR in comparison to enzyme immunoassay and culture","volume":"47","author":"Grys","year":"2009","journal-title":"J\u00a0Clin Microbiol"},{"issue":"8","key":"10.1016\/j.mayocp.2016.05.015_bib38","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1093\/cid\/cis1218","article-title":"Duration of fecal shedding of Shiga toxin-producing Escherichia coli O104:H4 in patients infected during the 2011 outbreak in Germany: a multicenter study","volume":"56","author":"Vonberg","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.mayocp.2016.05.015_bib39","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1093\/ndt\/gfs394","article-title":"Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry","volume":"27","author":"Kielstein","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.mayocp.2016.05.015_bib40","doi-asserted-by":"crossref","first-page":"e4565","DOI":"10.1136\/bmj.e4565","article-title":"Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study","volume":"345","author":"Menne","year":"2012","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.mayocp.2016.05.015_bib41","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/jca.21276","article-title":"Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue","volume":"28","author":"Schwartz","year":"2013","journal-title":"J\u00a0Clin Apher"},{"issue":"6","key":"10.1016\/j.mayocp.2016.05.015_bib42","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJM199108083250604","article-title":"Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group","volume":"325","author":"Rock","year":"1991","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.mayocp.2016.05.015_bib43","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1056\/NEJM199108083250605","article-title":"Improved survival in thrombotic thrombocytopenic purpura hemolytic uremic syndrome\u2014clinical-experience in 108 patients","volume":"325","author":"Bell","year":"1991","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.mayocp.2016.05.015_bib44","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/00005792-200301000-00003","article-title":"High-dose plasma infusion versus plasma exchange as early treatment of thrombotic thrombocytopenic purpura\/hemolytic-uremic syndrome","volume":"82","author":"Coppo","year":"2003","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.mayocp.2016.05.015_bib45","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1365-2141.2008.07292.x","article-title":"Methylene blue-photoinactivated plasma versus quarantine fresh frozen plasma in thrombotic thrombocytopenic purpura: a multicentric, prospective cohort study","volume":"143","author":"del R\u00edo-Garma","year":"2008","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.mayocp.2016.05.015_bib46","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1423-0410.2007.00940.x","article-title":"Cryosupernatant and solvent detergent fresh-frozen plasma (Octaplas) usage at a single centre in acute thrombotic thrombocytopenic purpura","volume":"93","author":"Scully","year":"2007","journal-title":"Vox Sang"},{"issue":"1","key":"10.1016\/j.mayocp.2016.05.015_bib47","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/jca.1003","article-title":"Cryoprecipitate poor plasma does not improve early response in primary adult thrombotic thrombocytopenic purpura (TTP)","volume":"16","author":"Zeigler","year":"2001","journal-title":"J\u00a0Clin Apher"},{"issue":"1","key":"10.1016\/j.mayocp.2016.05.015_bib48","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1365-2141.2005.05418.x","article-title":"Does cryosupernatant plasma improve outcome in thrombotic thrombocytopenic purpura? No answer yet","volume":"129","author":"Rock","year":"2005","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.mayocp.2016.05.015_bib49","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/(SICI)1098-1101(1998)13:1<16::AID-JCA3>3.0.CO;2-C","article-title":"Cellular source of serum lactate dehydrogenase elevation in patients with thrombotic thrombocytopenic purpura","volume":"13","author":"Cohen","year":"1998","journal-title":"J\u00a0Clin Apher"},{"issue":"4","key":"10.1016\/j.mayocp.2016.05.015_bib50","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/jca.20017","article-title":"Frequency and significance of schistocytes in TTP\/HUS patients at the discontinuation of plasma exchange therapy","volume":"19","author":"Egan","year":"2004","journal-title":"J\u00a0Clin Apher"},{"issue":"3","key":"10.1016\/j.mayocp.2016.05.015_bib51","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/(SICI)1098-1101(1998)13:3<133::AID-JCA7>3.0.CO;2-Z","article-title":"United States Thrombotic Thrombocytopenic Purpura Apheresis Study Group (US TTP ASG): multicenter survey and retrospective analysis of current efficacy of therapeutic plasma exchange","volume":"13","author":"Bandarenko","year":"1998","journal-title":"J\u00a0Clin Apher"},{"issue":"10","key":"10.1016\/j.mayocp.2016.05.015_bib52","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1182\/blood-2014-10-559211","article-title":"The role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpura","volume":"125","author":"Lim","year":"2015","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.mayocp.2016.05.015_bib53","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1537-2995.2007.01530.x","article-title":"Twice-daily plasma exchange for patients with refractory thrombotic thrombocytopenic purpura: the experience of the Oklahoma Registry, 1989 through 2006","volume":"48","author":"Nguyen","year":"2008","journal-title":"Transfusion"},{"issue":"2","key":"10.1016\/j.mayocp.2016.05.015_bib54","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1046\/j.1365-2141.1996.d01-1800.x","article-title":"Cryosupernatant as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. Members of the Canadian Apheresis Group","volume":"94","author":"Rock","year":"1996","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.mayocp.2016.05.015_bib55","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/ajh.2830340303","article-title":"Effectiveness of the cryosupernatant fraction of plasma in the treatment of refractory thrombotic thrombocytopenic purpura","volume":"34","author":"Byrnes","year":"1990","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.mayocp.2016.05.015_bib56","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/CCM.0b013e31822e9d66","article-title":"Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange: experience of the French Thrombotic Microangiopathies Reference Center","volume":"40","author":"Froissart","year":"2012","journal-title":"Crit Care Med"},{"key":"10.1016\/j.mayocp.2016.05.015_bib57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4137\/CMBD.S25326","article-title":"Efficacy and safety of rituximab for refractory and relapsing thrombotic thrombocytopenic purpura: a cohort of 10 cases","volume":"8","author":"Omri","year":"2015","journal-title":"Clin Med Insights Blood Disord"},{"issue":"6","key":"10.1016\/j.mayocp.2016.05.015_bib58","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1111\/j.1538-7836.2010.03818.x","article-title":"Rituximab pharmacokinetics during the management of acute idiopathic thrombotic thrombocytopenic purpura","volume":"8","author":"McDonald","year":"2010","journal-title":"J\u00a0Thromb Haemost"},{"issue":"3","key":"10.1016\/j.mayocp.2016.05.015_bib59","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S1470-2045(14)70005-1","article-title":"Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study","volume":"15","author":"Davies","year":"2014","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.mayocp.2016.05.015_bib60","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1111\/j.1537-2995.2012.03578.x","article-title":"Splenectomy and\/or cyclophosphamide as salvage therapies in thrombotic thrombocytopenic purpura: the French TMA Reference Center experience","volume":"52","author":"Beloncle","year":"2012","journal-title":"Transfusion"},{"issue":"5","key":"10.1016\/j.mayocp.2016.05.015_bib61","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/j.1365-2141.2005.05512.x","article-title":"The course of ADAMTS-13 activity and inhibitor titre in the treatment of thrombotic thrombocytopenic purpura with plasma exchange and vincristine","volume":"129","author":"Bohm","year":"2005","journal-title":"Br J Haematol"},{"issue":"Suppl 1","key":"10.1016\/j.mayocp.2016.05.015_bib62","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1538-7836.2011.04341.x","article-title":"Natural history of Upshaw-Schulman syndrome based on ADAMTS13 gene analysis in Japan","volume":"9","author":"Fujimura","year":"2011","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.mayocp.2016.05.015_bib63","series-title":"GeneReviews(R)","article-title":"Disorders of intracellular cobalamin metabolism","author":"Carrillo-Carrasco","year":"1993"},{"issue":"7","key":"10.1016\/j.mayocp.2016.05.015_bib64","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1007\/s00467-015-3110-x","article-title":"Nephrotic syndrome and thrombotic microangiopathy caused by cobalamin C deficiency","volume":"30","author":"Koenig","year":"2015","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"10.1016\/j.mayocp.2016.05.015_bib65","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1053\/j.ajkd.2013.08.031","article-title":"Adult-onset eculizumab-resistant hemolytic uremic syndrome associated with cobalamin C deficiency","volume":"63","author":"Cornec-Le Gall","year":"2014","journal-title":"Am J Kidney Dis"},{"issue":"9997","key":"10.1016\/j.mayocp.2016.05.015_bib66","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0140-6736(15)00076-8","article-title":"Adult-onset renal thrombotic microangiopathy and pulmonary arterial hypertension in cobalamin C deficiency","volume":"386","author":"Grang\u00e9","year":"2015","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.mayocp.2016.05.015_bib67","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1007\/s10545-009-1257-y","article-title":"Hydroxocobalamin dose escalation improves metabolic control in cblC","volume":"32","author":"Carrillo-Carrasco","year":"2009","journal-title":"J\u00a0Inherit Metab Dis"},{"issue":"1","key":"10.1016\/j.mayocp.2016.05.015_bib68","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2169\/internalmedicine.49.2706","article-title":"Registry of 919 patients with thrombotic microangiopathies across Japan: database of Nara Medical University during 1998-2008","volume":"49","author":"Fujimura","year":"2010","journal-title":"Intern Med"},{"issue":"1","key":"10.1016\/j.mayocp.2016.05.015_bib69","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1182\/blood.V80.1.241.241","article-title":"Characterization of multiple quinine-dependent antibodies in a patient with episodic hemolytic uremic syndrome and immune agranulocytosis","volume":"80","author":"Stroncek","year":"1992","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.mayocp.2016.05.015_bib70","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.7326\/0003-4819-135-12-200112180-00008","article-title":"Quinine-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: frequency, clinical features, and long-term outcomes","volume":"135","author":"Kojouri","year":"2001","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.mayocp.2016.05.015_bib71","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0272-6386(89)80032-0","article-title":"Renal vascular and thrombotic effects of cyclosporine","volume":"13","author":"Remuzzi","year":"1989","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"10.1016\/j.mayocp.2016.05.015_bib72","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s11912-012-0242-z","article-title":"VEGF inhibition, hypertension, and renal toxicity","volume":"14","author":"Hayman","year":"2012","journal-title":"Curr Oncol Rep"},{"issue":"12","key":"10.1016\/j.mayocp.2016.05.015_bib73","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.jacc.2007.04.093","article-title":"Two mechanistic pathways for thienopyridine-associated thrombotic thrombocytopenic purpura: a report from the SERF-TTP Research Group and the RADAR Project","volume":"50","author":"Bennett","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.mayocp.2016.05.015_bib74","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/ctr.12170","article-title":"Successful conversion to belatacept after thrombotic microangiopathy in kidney transplant patients","volume":"27","author":"Koppula","year":"2013","journal-title":"Clin Transplant"},{"issue":"9","key":"10.1016\/j.mayocp.2016.05.015_bib75","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/ajh.22091","article-title":"Systemic infections mimicking thrombotic thrombocytopenic purpura","volume":"86","author":"Booth","year":"2011","journal-title":"Am\u00a0J Hematol"},{"issue":"8046","key":"10.1016\/j.mayocp.2016.05.015_bib76","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/S0140-6736(77)92915-4","article-title":"Thomsen-Friedenreich antigen in haemolytic-uraemic syndrome","volume":"2","author":"Klein","year":"1977","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.mayocp.2016.05.015_bib77","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jpeds.2007.03.055","article-title":"Hemolytic uremic syndrome associated with invasive pneumococcal disease: the United kingdom experience","volume":"151","author":"Waters","year":"2007","journal-title":"J\u00a0Pediatr"},{"issue":"2","key":"10.1016\/j.mayocp.2016.05.015_bib78","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/MOP.0b013e32835d7f2c","article-title":"Update on Streptococcus pneumoniae associated hemolytic uremic syndrome","volume":"25","author":"Spinale","year":"2013","journal-title":"Curr Opin Pediatr"},{"issue":"6","key":"10.1016\/j.mayocp.2016.05.015_bib79","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.semnephrol.2008.08.007","article-title":"Thrombotic microangiopathy and other glomerular disorders in the HIV-infected patient","volume":"28","author":"Fine","year":"2008","journal-title":"Semin Nephrol"},{"issue":"3","key":"10.1016\/j.mayocp.2016.05.015_bib80","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1365-3083.2008.02143.x","article-title":"Human immunodeficiency virus-associated thrombotic microangiopathies: clinical characteristics and outcome according to ADAMTS13 activity","volume":"68","author":"Malak","year":"2008","journal-title":"Scand J Immunol"},{"issue":"24","key":"10.1016\/j.mayocp.2016.05.015_bib81","doi-asserted-by":"crossref","first-page":"5888","DOI":"10.1182\/blood-2012-02-408914","article-title":"Unexpected frequency of Upshaw-Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura","volume":"119","author":"Moatti-Cohen","year":"2012","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.mayocp.2016.05.015_bib82","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1182\/blood-2014-02-553131","article-title":"Thrombotic thrombocytopenic purpura and pregnancy: presentation, management, and subsequent pregnancy outcomes","volume":"124","author":"Scully","year":"2014","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.mayocp.2016.05.015_bib83","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1681\/ASN.2009070706","article-title":"Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations","volume":"21","author":"Fakhouri","year":"2010","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.mayocp.2016.05.015_bib84","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3109\/10641963.2010.503303","article-title":"Clinical features of malignant hypertension with thrombotic microangiopathy","volume":"33","author":"Akimoto","year":"2011","journal-title":"Clin Exp Hypertens"},{"issue":"6","key":"10.1016\/j.mayocp.2016.05.015_bib85","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.semarthrit.2014.12.001","article-title":"Scleroderma renal crisis","volume":"44","author":"Bose","year":"2015","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.mayocp.2016.05.015_bib86","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1160\/TH08-12-0825","article-title":"Heterogeneous pathogenic processes of thrombotic microangiopathies in patients with connective tissue diseases","volume":"102","author":"Matsuyama","year":"2009","journal-title":"Thromb Haemost"},{"issue":"4","key":"10.1016\/j.mayocp.2016.05.015_bib87","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1634\/theoncologist.8-4-375","article-title":"Thrombotic thrombocytopenic purpura associated with bone marrow metastasis and secondary myelofibrosis in cancer","volume":"8","author":"Chang","year":"2003","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.mayocp.2016.05.015_bib88","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1634\/theoncologist.12-1-11","article-title":"Disseminated malignancy misdiagnosed as thrombotic thrombocytopenic purpura: a report of 10 patients and a systematic review of published cases","volume":"12","author":"Francis","year":"2007","journal-title":"Oncologist"},{"issue":"8","key":"10.1016\/j.mayocp.2016.05.015_bib89","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1634\/theoncologist.2009-0067","article-title":"Cancer awareness in atypical thrombotic microangiopathies","volume":"14","author":"Oberic","year":"2009","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.mayocp.2016.05.015_bib90","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1600-0609.2010.01448.x","article-title":"Cancer-associated microangiopathic hemolytic anemia with thrombocytopenia: an important diagnostic consideration","volume":"85","author":"Elliott","year":"2010","journal-title":"Eur J Haematol"},{"issue":"4","key":"10.1016\/j.mayocp.2016.05.015_bib91","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/MD.0b013e3182603598","article-title":"Cancer-related microangiopathic hemolytic anemia: clinical and laboratory features in 168 reported cases","volume":"91","author":"Lechner","year":"2012","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"10.1016\/j.mayocp.2016.05.015_bib92","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.kint.2015.12.003","article-title":"Diagnosis of complement alternative pathway disorders","volume":"89","author":"Angioi","year":"2016","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.mayocp.2016.05.015_bib93","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/ki.2013.373","article-title":"Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children","volume":"85","author":"Sinha","year":"2014","journal-title":"Kidney Int"},{"issue":"23","key":"10.1016\/j.mayocp.2016.05.015_bib94","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.mayocp.2016.05.015_bib95","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/ki.2014.423","article-title":"Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies","volume":"87","author":"Licht","year":"2015","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.mayocp.2016.05.015_bib96","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1053\/ajkd.2003.50058","article-title":"De novo thrombotic microangiopathy in renal transplant recipients: a comparison of hemolytic uremic syndrome with localized renal thrombotic microangiopathy","volume":"41","author":"Schwimmer","year":"2003","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"10.1016\/j.mayocp.2016.05.015_bib97","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1111\/j.1600-6143.2010.03156.x","article-title":"Thrombotic microangiopathy after kidney transplantation","volume":"10","author":"Noris","year":"2010","journal-title":"Am J Transplant"},{"issue":"3","key":"10.1016\/j.mayocp.2016.05.015_bib98","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/ajt.12077","article-title":"Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome","volume":"13","author":"Le Quintrec","year":"2013","journal-title":"Am J Transplant"},{"issue":"3","key":"10.1016\/j.mayocp.2016.05.015_bib99","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/MOT.0000000000000074","article-title":"Thrombotic microangiopathy in renal allografts: the diagnostic challenge","volume":"19","author":"Nadasdy","year":"2014","journal-title":"Curr Opin Organ Transplant"},{"issue":"2","key":"10.1016\/j.mayocp.2016.05.015_bib100","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/ajt.12590","article-title":"Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions","volume":"14","author":"Haas","year":"2014","journal-title":"Am J Transplant"},{"issue":"10","key":"10.1016\/j.mayocp.2016.05.015_bib101","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1097\/TP.0000000000000184","article-title":"Report of the inefficacy of eculizumab in two cases of severe antibody-mediated rejection of renal grafts","volume":"98","author":"Burbach","year":"2014","journal-title":"Transplantation"},{"issue":"6","key":"10.1016\/j.mayocp.2016.05.015_bib102","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1016\/j.transproceed.2015.06.029","article-title":"Eculizumab for treatment of refractory antibody-mediated rejection in kidney transplant patients: a single-center experience","volume":"47","author":"Yelken","year":"2015","journal-title":"Transplant Proc"},{"issue":"1","key":"10.1016\/j.mayocp.2016.05.015_bib103","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3324\/haematol.10699","article-title":"Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group","volume":"92","author":"Ruutu","year":"2007","journal-title":"Haematologica"},{"issue":"21","key":"10.1016\/j.mayocp.2016.05.015_bib104","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.739.739","article-title":"Tacrolimus\/sirolimus vs. tacrolimus\/methotrexate for graft-vs.-host disease prophylaxis after HLA-matched, related donor hematopoietic stem cell transplantation: results of Blood and Marrow Transplant Clinical Trials Network Trial 0402","volume":"120","author":"Cutler","year":"2012","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.mayocp.2016.05.015_bib105","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1182\/blood-2013-05-501445","article-title":"Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy","volume":"122","author":"Jodele","year":"2013","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.mayocp.2016.05.015_bib106","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1537-2995.2004.00700.x","article-title":"Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome following allogeneic HPC transplantation: a diagnostic dilemma","volume":"44","author":"George","year":"2004","journal-title":"Transfusion"},{"issue":"8","key":"10.1016\/j.mayocp.2016.05.015_bib107","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.bbmt.2005.06.001","article-title":"Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation","volume":"11","author":"Ho","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"10.1016\/j.mayocp.2016.05.015_bib108","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1097\/TP.0b013e3181f24e8d","article-title":"Validation of recently proposed consensus criteria for thrombotic microangiopathy after allogeneic hematopoietic stem-cell transplantation","volume":"90","author":"Cho","year":"2010","journal-title":"Transplantation"},{"issue":"4","key":"10.1016\/j.mayocp.2016.05.015_bib109","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1182\/blood-2014-03-564997","article-title":"Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults","volume":"124","author":"Jodele","year":"2014","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.mayocp.2016.05.015_bib110","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/jca.21352","article-title":"Outcomes of plasma exchange in patients with transplant-associated thrombotic microangiopathy based on time of presentation since transplant","volume":"30","author":"Mulay","year":"2015","journal-title":"J\u00a0Clin Apher"},{"issue":"3","key":"10.1016\/j.mayocp.2016.05.015_bib111","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/j.1537-2995.2012.03776.x","article-title":"Does early initiation of therapeutic plasma exchange improve outcome in pediatric stem cell transplant-associated thrombotic microangiopathy?","volume":"53","author":"Jodele","year":"2013","journal-title":"Transfusion"},{"issue":"4","key":"10.1016\/j.mayocp.2016.05.015_bib112","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.bbmt.2013.12.565","article-title":"Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy","volume":"20","author":"Jodele","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"10.1016\/j.mayocp.2016.05.015_bib113","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2215\/CJN.02210310","article-title":"Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype","volume":"5","author":"Noris","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.mayocp.2016.05.015_bib114","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1182\/blood-2005-10-007252","article-title":"Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome","volume":"108","author":"Caprioli","year":"2006","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.mayocp.2016.05.015_bib115","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1681\/ASN.2013080886","article-title":"Phenotypic expansion of DGKE-associated diseases","volume":"25","author":"Westland","year":"2014","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"8","key":"10.1016\/j.mayocp.2016.05.015_bib116","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1182\/blood-2009-09-243790","article-title":"Survival and relapse in patients with thrombotic thrombocytopenic purpura","volume":"115","author":"Kremer Hovinga","year":"2010","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.mayocp.2016.05.015_bib117","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1182\/blood-2006-02-006064","article-title":"Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity","volume":"109","author":"Ferrari","year":"2007","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.mayocp.2016.05.015_bib118","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3324\/haematol.11739","article-title":"ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission","volume":"93","author":"Peyvandi","year":"2008","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.mayocp.2016.05.015_bib119","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1053\/j.seminhematol.2011.08.004","article-title":"Practical issues in ADAMTS13 testing and emerging therapies in thrombotic thrombocytopenic purpura","volume":"48","author":"Cataland","year":"2011","journal-title":"Semin Hematol"},{"issue":"2","key":"10.1016\/j.mayocp.2016.05.015_bib120","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1182\/blood-2014-01-550244","article-title":"Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura","volume":"124","author":"Hie","year":"2014","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.mayocp.2016.05.015_bib121","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/j.1365-2141.2008.07107.x","article-title":"Relationship between ADAMTS13 activity in clinical remission and the risk of TTP relapse","volume":"141","author":"Jin","year":"2008","journal-title":"Br J Haematol"},{"issue":"Suppl 1","key":"10.1016\/j.mayocp.2016.05.015_bib122","first-page":"s153","article-title":"A\u00a0first bout of thrombotic thrombocytopenic purpura triggered by herpes simplex infection in a 45-year-old nulliparous female with Upshaw-Schulman syndrome","volume":"12","author":"Morioka","year":"2014","journal-title":"Blood Transfus"},{"issue":"2","key":"10.1016\/j.mayocp.2016.05.015_bib123","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1182\/blood-2012-01-403113","article-title":"Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura","volume":"120","author":"Lotta","year":"2012","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.mayocp.2016.05.015_bib124","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1182\/blood-2013-11-538900","article-title":"Pregnancy outcomes following recovery from acquired thrombotic thrombocytopenic purpura","volume":"123","author":"Jiang","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.mayocp.2016.05.015_bib125","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1053\/j.ajkd.2015.04.010","article-title":"Discontinuation of eculizumab treatment in atypical hemolytic uremic syndrome: an update","volume":"66","author":"Ardissino","year":"2015","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1016\/j.mayocp.2016.05.015_bib126","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1053\/j.ajkd.2014.04.039","article-title":"Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome","volume":"65","author":"Wetzels","year":"2015","journal-title":"Am J Kidney Dis"},{"issue":"23","key":"10.1016\/j.mayocp.2016.05.015_bib127","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1182\/blood-2015-02-629683","article-title":"Modified Ham test for atypical hemolytic uremic syndrome","volume":"125","author":"Gavriilaki","year":"2015","journal-title":"Blood"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619616302580?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619616302580?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T18:07:28Z","timestamp":1718734048000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619616302580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":127,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S0025619616302580"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2016.05.015","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thrombotic Microangiopathy Care Pathway: A Consensus Statement for the Mayo Clinic Complement Alternative Pathway-Thrombotic Microangiopathy (CAP-TMA) Disease-Oriented Group","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2016.05.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Mayo Foundation for Medical Education and Research","name":"copyright","label":"Copyright"}]}}